This HTML5 document contains 140 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://linked.opendata.cz/resource/drugbank/drug/DB00165/identifier/wikipedia/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00165/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00165/identifier/kegg-compound/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/mixture/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00165/identifier/drugbank/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00165/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00165
rdf:type
n3:Drug
n3:description
Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Pyridoxal 5-phosphate is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and vitamin B6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading. [PubChem]
n3:dosage
n8:271B4F91-363D-11E5-9242-09173F13E4C5
n3:group
nutraceutical approved
n3:halfLife
15-20 days
n3:indication
For the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.
n3:manufacturer
n7:271B4F7D-363D-11E5-9242-09173F13E4C5 n7:271B4F7E-363D-11E5-9242-09173F13E4C5 n7:271B4F7B-363D-11E5-9242-09173F13E4C5 n7:271B4F7C-363D-11E5-9242-09173F13E4C5 n7:271B4F79-363D-11E5-9242-09173F13E4C5 n7:271B4F7A-363D-11E5-9242-09173F13E4C5 n7:271B4F77-363D-11E5-9242-09173F13E4C5 n7:271B4F78-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00165 n25:DB00165
dcterms:title
Pyridoxine
adms:identifier
n11:DB00165 n13:16709 n18:Pyridoxine n22:C00314 n24:PA451897
n3:mechanismOfAction
Vitamin B6 is the collective term for a group of three related compounds, pyridoxine (PN), pyridoxal (PL) and pyridoxamine (PM), and their phosphorylated derivatives, pyridoxine 5'-phosphate (PNP), pyridoxal 5'-phosphate (PLP) and pyridoxamine 5'-phosphate (PMP). Although all six of these compounds should technically be referred to as vitamin B6, the term vitamin B6 is commonly used interchangeably with just one of them, pyridoxine. Vitamin B6, principally in its biologically active coenzyme form pyridoxal 5'-phosphate, is involved in a wide range of biochemical reactions, including the metabolism of amino acids and glycogen, the synthesis of nucleic acids, hemogloblin, sphingomyelin and other sphingolipids, and the synthesis of the neurotransmitters serotonin, dopamine, norepinephrine and gamma-aminobutyric acid (GABA).
n3:packager
n7:271B4F47-363D-11E5-9242-09173F13E4C5 n7:271B4F60-363D-11E5-9242-09173F13E4C5 n7:271B4F61-363D-11E5-9242-09173F13E4C5 n7:271B4F4A-363D-11E5-9242-09173F13E4C5 n7:271B4F4B-363D-11E5-9242-09173F13E4C5 n7:271B4F48-363D-11E5-9242-09173F13E4C5 n7:271B4F49-363D-11E5-9242-09173F13E4C5 n7:271B4F4E-363D-11E5-9242-09173F13E4C5 n7:271B4F4F-363D-11E5-9242-09173F13E4C5 n7:271B4F4C-363D-11E5-9242-09173F13E4C5 n7:271B4F4D-363D-11E5-9242-09173F13E4C5 n7:271B4F5B-363D-11E5-9242-09173F13E4C5 n7:271B4F5E-363D-11E5-9242-09173F13E4C5 n7:271B4F5F-363D-11E5-9242-09173F13E4C5 n7:271B4F5C-363D-11E5-9242-09173F13E4C5 n7:271B4F5D-363D-11E5-9242-09173F13E4C5 n7:271B4F52-363D-11E5-9242-09173F13E4C5 n7:271B4F53-363D-11E5-9242-09173F13E4C5 n7:271B4F50-363D-11E5-9242-09173F13E4C5 n7:271B4F51-363D-11E5-9242-09173F13E4C5 n7:271B4F56-363D-11E5-9242-09173F13E4C5 n7:271B4F57-363D-11E5-9242-09173F13E4C5 n7:271B4F54-363D-11E5-9242-09173F13E4C5 n7:271B4F55-363D-11E5-9242-09173F13E4C5 n7:271B4F5A-363D-11E5-9242-09173F13E4C5 n7:271B4F62-363D-11E5-9242-09173F13E4C5 n7:271B4F58-363D-11E5-9242-09173F13E4C5 n7:271B4F59-363D-11E5-9242-09173F13E4C5 n7:271B4F65-363D-11E5-9242-09173F13E4C5 n7:271B4F66-363D-11E5-9242-09173F13E4C5 n7:271B4F63-363D-11E5-9242-09173F13E4C5 n7:271B4F64-363D-11E5-9242-09173F13E4C5 n7:271B4F69-363D-11E5-9242-09173F13E4C5 n7:271B4F6A-363D-11E5-9242-09173F13E4C5 n7:271B4F67-363D-11E5-9242-09173F13E4C5 n7:271B4F68-363D-11E5-9242-09173F13E4C5 n7:271B4F6D-363D-11E5-9242-09173F13E4C5 n7:271B4F6E-363D-11E5-9242-09173F13E4C5 n7:271B4F6B-363D-11E5-9242-09173F13E4C5 n7:271B4F6C-363D-11E5-9242-09173F13E4C5 n7:271B4F71-363D-11E5-9242-09173F13E4C5 n7:271B4F72-363D-11E5-9242-09173F13E4C5 n7:271B4F6F-363D-11E5-9242-09173F13E4C5 n7:271B4F70-363D-11E5-9242-09173F13E4C5 n7:271B4F75-363D-11E5-9242-09173F13E4C5 n7:271B4F76-363D-11E5-9242-09173F13E4C5 n7:271B4F73-363D-11E5-9242-09173F13E4C5 n7:271B4F74-363D-11E5-9242-09173F13E4C5
n3:synonym
5-Hydroxy-6-methyl-3,4-pyridinedimethanol 3-Hydroxy-4,5-dimethylol-alpha-picoline 3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine Vitamin B6 Pyridoxine 2-Methyl-3-hydroxy-4,5-dihydroxymethylpyridine Pyridoxol
n3:toxicity
Oral Rat LD50 = 4 gm/kg. Toxic effects include convulsions, dyspnea, hypermotility, diarrhea, ataxia and muscle weakness.
n19:hasAHFSCode
n20:92-02-00%2A n20:88-08-00
n3:mixture
n12:271B4F46-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
22%
n3:salt
n3:synthesisReference
Harumi Kita, "Production of pyridoxine." U.S. Patent US4339586, issued October, 1972.
n14:hasConcept
n15:M0018247
foaf:page
n6:vit_0215.shtml n21:pyridoxine-vitamin-b6-extended-release-tablets.html
n3:IUPAC-Name
n4:271B4F96-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4F9C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4F9B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4F98-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4F99-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4F9A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4F94-363D-11E5-9242-09173F13E4C5 n4:271B4FAC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4F92-363D-11E5-9242-09173F13E4C5 n4:271B4F95-363D-11E5-9242-09173F13E4C5 n4:271B4FAE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4F93-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4FA2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4FA3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4F9D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4F9E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4FA0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4F9F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4FA1-363D-11E5-9242-09173F13E4C5
n3:absorption
The B vitamins are readily absorbed from the gastrointestinal tract, except in malabsorption syndromes. Pyridoxine is absorbed mainly in the jejunum.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
65-23-6
n3:category
n3:containedIn
n9:271B4F81-363D-11E5-9242-09173F13E4C5 n9:271B4F82-363D-11E5-9242-09173F13E4C5 n9:271B4F7F-363D-11E5-9242-09173F13E4C5 n9:271B4F80-363D-11E5-9242-09173F13E4C5 n9:271B4F85-363D-11E5-9242-09173F13E4C5 n9:271B4F86-363D-11E5-9242-09173F13E4C5 n9:271B4F83-363D-11E5-9242-09173F13E4C5 n9:271B4F84-363D-11E5-9242-09173F13E4C5 n9:271B4F89-363D-11E5-9242-09173F13E4C5 n9:271B4F8A-363D-11E5-9242-09173F13E4C5 n9:271B4F87-363D-11E5-9242-09173F13E4C5 n9:271B4F88-363D-11E5-9242-09173F13E4C5 n9:271B4F8D-363D-11E5-9242-09173F13E4C5 n9:271B4F8E-363D-11E5-9242-09173F13E4C5 n9:271B4F8B-363D-11E5-9242-09173F13E4C5 n9:271B4F8C-363D-11E5-9242-09173F13E4C5 n9:271B4F8F-363D-11E5-9242-09173F13E4C5 n9:271B4F90-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4FA8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4FAA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4FAB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4FAD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4FA7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4FA6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4FA9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4F97-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4FA4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4FA5-363D-11E5-9242-09173F13E4C5